bimekizumab

Home
Ligands
bimekizumab

GtoPdb Ligand ID: 9411

Synonyms: bimekizumab-bkzx | Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1

bimekizumab is an approved drug (EMA (2021), FDA (2023))

Comment: Bimekizumab (UCB4940) is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis were reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].

No information available.

No information available.

Summary of Clinical Use
First-in-human clinical trial was NCT02529956, which reported clinically meaningful efficacy [2] and led to further development of bimekizumab in IL-17A- and IL-17 F-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, chronic plaque psoriasis and ankylosing ppondylitis. Click here to link to ClinicalTrials.gov's list of Phase 2 bimekizumab trials. The EMA approved bimekizumab as a treatment for psoriasis in August 2021.

Summary of Clinical Use

First-in-human clinical trial was NCT02529956, which reported clinically meaningful efficacy [2] and led to further development of bimekizumab in IL-17A- and IL-17 F-mediated diseases, including rheumatoid arthritis, psoriatic arthritis, chronic plaque psoriasis and ankylosing ppondylitis. Click here to link to ClinicalTrials.gov's list of Phase 2 bimekizumab trials.
The EMA approved bimekizumab as a treatment for psoriasis in August 2021.

Mechanism Of Action and Pharmacodynamic Effects
Antibody binds to IL-17A, IL-17F and the IL-17A/F heterodimer, neutralising their biological activity [1]. Dual antagonists of IL-17A and IL-17F may be more effective than a sole antagonist in treating IL-17 mediated diseases.

Mechanism Of Action and Pharmacodynamic Effects

Antibody binds to IL-17A, IL-17F and the IL-17A/F heterodimer, neutralising their biological activity [1]. Dual antagonists of IL-17A and IL-17F may be more effective than a sole antagonist in treating IL-17 mediated diseases.